About the Company
harnessing novel t cell systems to extend the promise of immunotherapy
Please visit tscan.com for more information about the company.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
127
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TCRX News
Hedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16%
Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to ...
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
Feb. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell ...
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.78 per share a year ago.
TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline
Warning! GuruFocus has detected 6 Warning Signs with TCRX. On March 6, 2024, TScan Therapeutics Inc (NASDAQ:TCRX) released its 8-K filing, announcing its financial results for the fourth quarter ...
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT an ...
TScan Therapeutics Inc TCRX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies ...
TCRX TScan Therapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.78 per share a year ago. These ...
TScan Therapeutics, Inc.: TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell ...
Loading the latest forecasts...